Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) just unveiled an announcement.
Recce Pharmaceuticals made corrections to its Appendix 4C Cash Flow Report for the quarter ending December 31, 2024, reversing the net cash outflows to inflows and adjusting the previous quarter’s cash balance. These corrections do not impact the quarter-end cash balance, highlighting a positive outlook for the company’s financial health.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd, listed on ASX and FSE, is developing a new class of synthetic anti-infectives designed to tackle antibiotic-resistant superbugs and emerging viral pathogens. The company’s product pipeline includes patented therapies such as RECCE 327 for severe bacterial infections, RECCE 435 for bacterial infections, and RECCE 529 for viral infections. Recognized by WHO and FDA for its innovative approach to combating antimicrobial resistance, Recce holds market exclusivity for its products and operates its manufacturing in support of clinical trials.
YTD Price Performance: -8.33%
Average Trading Volume: 122,483
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$102M
For an in-depth examination of RCE stock, go to TipRanks’ Stock Analysis page.
